Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Anita Garrett

Physician Assistant Bakersfield, CA Physician Assistant

NPI 1962527366 CMS profile 10583020

5101 Commerce Dr, Suite 101, Bakersfield, CA 93309

Open in the dashboard

General payments

$40,721

583 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Anita Garrett of Bakersfield, CA is reported in the CMS Open Payments database as having received $40,721 across 583 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $7,775 122
2024 General $9,963 143
2023 General $11,579 151
2022 General $8,440 121
2021 General $2,964 46

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Anita Garrett
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Anita Garrett were reported at $7,775. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Anita Garrett Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $2,964 $132 $37–$438 $132
2022 $8,440 $155 $48–$522 $149
2023 $11,579 $167 $52–$557 $160
2024 $9,963 $178 $55–$600 $164
2025 $7,775 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $31,037 207 payments
  2. Janssen Biotech, Inc. $1,719 88 payments
  3. Incyte Corporation $842 29 payments
  4. Amgen Inc. $842 30 payments
  5. Novartis Pharmaceuticals Corporation $834 27 payments
  6. E.R. Squibb & Sons, L.L.C. $796 24 payments
  7. Arcutis Biotherapeutics, Inc. $737 15 payments
  8. Genzyme Corporation $594 19 payments
  9. Sun Pharmaceutical Industries Inc. $574 23 payments
  10. UCB, Inc. $484 18 payments
  11. Other $2,262 103 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $24,688 25 payments
  2. Food and Beverage $14,218 545 payments
  3. Travel and Lodging $1,472 6 payments
  4. Education $343 7 payments
Products named General payments · program years 2021–2025
  1. SKYRIZI Immunology $13,743 83 payments
  2. RINVOQ $13,682 101 payments
  3. SKYRIZI Immunology $5,294 19 payments
  4. TREMFYA $1,757 82 payments
  5. Otezla $842 30 payments
  6. SOTYKTU $796 24 payments
  7. OPZELURA $728 27 payments
  8. COSENTYX $698 20 payments
  9. DUPIXENT $695 22 payments
  10. Zoryve $572 11 payments
  11. Other $3,978 195 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 23 drugs

Part D claims

887

Median for Physician Assistant: 241

Drug cost

$21,587

Median for Physician Assistant: $4,110

Branded share of claims

15.7%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Metronidazole Generic 54 $4,654
Fluorouracil Generic 43 $2,793
Fluocinonide Generic 60 $2,144
Doxycycline Hyclate Generic 54 $1,521
Triamcinolone Acetonide Generic 123 $1,428
Minocycline Hcl Generic 66 $1,396
Valacyclovir Valacyclovir Hcl Brand 55 $1,370
Ketoconazole Generic 34 $1,028
Mycophenolate Mofetil Generic 15 $928
Clobetasol Propionate Generic 11 $682

The 10 drugs with the highest cost, of 23 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SKYRIZI
  • AbbVie, Inc. $6,458
$6,458 — —
RINVOQ
  • AbbVie, Inc. $934
$934 — —
TREMFYA
  • Janssen Biotech, Inc. $456
$456 — —
Zoryve
  • Arcutis Biotherapeutics, Inc. $440
$440 — —
Otezla
  • Amgen Inc. $307
$307 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

583 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record